PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor

In our previous study, we found that inhibition of protein tyrosine phosphatase non-receptor type 3 (PTPN3), which is expressed in lymphocytes, enhances lymphocyte activation, suggesting PTPN3 may act as an immune checkpoint molecule. However, PTPN3 is also expressed in various cancers, and the biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Satoko, Onishi, Hideya, Masuda, Shogo, Fujimura, Akiko, Ichimiya, Shu, Nakayama, Kazunori, Imaizumi, Akira, Nishiyama, Kenichi, Kojima, Masayuki, Miyoshi, Kei, Nakamura, Katsuya, Umebayashi, Masayo, Morisaki, Takashi, Nakamura, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208899/
https://www.ncbi.nlm.nih.gov/pubmed/34134073
http://dx.doi.org/10.1016/j.tranon.2021.101152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208899/
https://www.ncbi.nlm.nih.gov/pubmed/34134073
http://dx.doi.org/10.1016/j.tranon.2021.101152

Ejemplares similares